Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.

You may also be interested in...



Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off

TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia

FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk

Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.

EU Suspends Avandia; Pressure On Open Decision-Making May Stay

Product will be taken off the market "within the next few months," EMA says as it holds an unprecedented press conference.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel